OverviewSuggest Edit

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

TypePublic
Founded2013
HQSan Diego, US
Websitemirati.com

Latest Updates

Employees (est.) (Feb 2019)51(+35%)
Job Openings4
Revenue (FY, 2018)$12.9 M
Share Price (Mar 2019)$75.4 (+4%)

Key People/Management at Mirati Therapeutics

Charles M. Baum

Charles M. Baum

President and CEO
Isan Chen

Isan Chen

Chief Medical and Development Officer
Chris Lemasters

Chris Lemasters

Chief Business Officer
James Christensen

James Christensen

Senior Vice President and Chief Scientific Officer
Jamie Donadio

Jamie Donadio

Senior Vice President and Chief Financial Officer
Perry C. Johnston

Perry C. Johnston

Vice President, Chief Legal and Compliance Officer, and Corporate Secretary
Show more

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
9393 Towne Centre Dr #200
Show all (1)
Report incorrect company information

Mirati Therapeutics Financials and Metrics

Mirati Therapeutics Revenue

Mirati Therapeutics's revenue was reported to be $12.93 m in FY, 2018
USD

Revenue (FY, 2018)

12.9m

Net income (FY, 2018)

(98.4m)

EBIT (FY, 2018)

(102.6m)

Market capitalization (21-Mar-2019)

2.7b

Closing stock price (21-Mar-2019)

75.4

Cash (31-Dec-2018)

32.7m
Mirati Therapeutics's current market capitalization is $2.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

12.9m

General and administrative expense

11.1m15.8m15.3m13.5m21.7m

R&D expense

19.8m49.0m68.5m58.1m93.9m

Operating expense total

32.0m64.7m83.8m71.5m115.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

9.5m

General and administrative expense

2.4m2.9m3.5m3.8m4.2m4.2m4.1m3.8m3.5m3.7m3.7m5.2m

R&D expense

5.2m7.2m7.0m8.2m11.3m14.6m18.0m18.4m16.1m14.4m15.0m19.7m

Operating expense total

8.0m10.1m10.5m12.0m15.5m18.7m22.1m22.2m19.6m18.1m18.6m24.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.2m6.6m49.5m22.4m107.7m32.7m

Accounts Receivable

Inventories

Current Assets

64.2m32.7m125.4m59.6m155.8m226.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

7.6m8.3m8.5m4.9m14.3m13.4m109.9m34.6m24.5m19.8m29.8m20.0m20.6m

Current Assets

17.0m56.0m49.2m40.3m71.2m60.9m141.0m109.9m93.0m75.5m107.9m92.3m153.1m

PP&E

427.0k275.0k479.0k524.0k667.0k693.0k639.0k601.0k558.0k537.0k638.0k618.0k484.0k

Total Assets

18.0m56.3m49.7m41.3m72.2m61.9m143.7m112.5m96.0m79.2m110.8m95.0m154.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(43.7m)(64.5m)(83.1m)(70.4m)(98.4m)

Depreciation and Amortization

171.0k199.0k212.0k180.0k184.0k175.0k

Inventories

Accounts Payable

(68.0k)4.4m5.2m(1.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(13.7m)(11.0m)(33.3m)(11.9m)(27.4m)(46.1m)(21.9m)(44.0m)(63.4m)(17.8m)(36.2m)(14.7m)

Depreciation and Amortization

105.0k154.0k100.0k153.0k101.0k139.0k91.0k41.0k

Accounts Payable

1.3m111.0k

Cash From Operating Activities

(35.8m)(7.9m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued

32

Patents Pending

1
Show all operating metrics
Report incorrect company information

Mirati Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Mirati Therapeutics News and Updates

Mirati Therapeutics To Present At Upcoming Healthcare Conferences

SAN DIEGO, March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39th Annual Healthcare Conference in Boston on Tuesday, March 12th at 11:20 a.m. ET/ 8:20 a.m. PT. Oppenheimer 29th...

Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT. Chris...

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are...

Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST. Charles M. Baum, M.D....

Mirati Therapeutics Added To NASDAQ Biotechnology Index

SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI). The Company's addition to the Index will become...

Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors

SAN DIEGO, Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately. Ms. Martinez-Davis is the President of...
Show more
Report incorrect company information

Mirati Therapeutics Blogs

Mirati Therapeutics Reports Fourth Quarter Financial Results

Mirati Therapeutics Reports Fourth Quarter Financial Results Content Import Thu, 02/28/2019 - 16:26 Mirati Therapeutics Reports Fourth Quarter Financial Results February 28, 2019 This release is a backfill from a News Wire Earnings …

Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors

SAN DIEGO , Feb. 19, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019 . Dr. Rodney Lappe Ph.D.

Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14 th at 11:00 a.m. ET / 8:00 a.m. PT .

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

SAN DIEGO , Jan. 22, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62 .00 per share.

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock Content Import Wed, 01/16/2019 - 16:04 Mirati Therapeutics Announces Proposed Public Offering Of Common Stock January 16, 2019 This release is a backfill from a News Wire Ge…

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor Content Import Tue, 01/15/2019 - 16:25 Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor …
Show more

Mirati Therapeutics Frequently Asked Questions

  • When was Mirati Therapeutics founded?

    Mirati Therapeutics was founded in 2013.

  • Who are Mirati Therapeutics key executives?

    Mirati Therapeutics's key executives are Charles M. Baum, Isan Chen and Chris Lemasters.

  • How many employees does Mirati Therapeutics have?

    Mirati Therapeutics has 51 employees.

  • What is Mirati Therapeutics revenue?

    Latest Mirati Therapeutics annual revenue is $12.9 m.

  • What is Mirati Therapeutics revenue per employee?

    Latest Mirati Therapeutics revenue per employee is $253.5 k.

  • Who are Mirati Therapeutics competitors?

    Competitors of Mirati Therapeutics include OncoStem Diagnostics, Heidelberg Pharma and MEI Pharma.

  • Where is Mirati Therapeutics headquarters?

    Mirati Therapeutics headquarters is located at 9393 Towne Centre Dr #200, San Diego.

  • Where are Mirati Therapeutics offices?

    Mirati Therapeutics has an office in San Diego.

  • How many offices does Mirati Therapeutics have?

    Mirati Therapeutics has 1 office.